Novelix Pharmaceuticals Ltd
Submission of intimation of allotment of equity shares.
FUNDRAISE
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 10 Jul 2026, 01:01 PM IST · BSE ID: 9b95fbb3-41ae-4603-8613-d02b114b0044
View Original BSE Filing (PDF)
💡
In Simple Terms
The company has issued new shares through two private sales, raising funds from both its main investors and others.
🤖 AI Summary
- Company allotted 33,75,000 equity shares via warrant conversion to promoters, raising Rs. 6.75 Crore.
- Additional 12,00,000 equity shares allotted to non-promoters via preferential issue, raising Rs. 6.84 Crore.
- Warrants were converted at Rs. 20/- per share, while new shares were issued at Rs. 57/- each.
- The company's paid-up equity capital increased from Rs. 23,89,50,000.00 to Rs. 27,27,00,000.00.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total number of equity shares allotted upon warrant conversion
33,75,000
Issue price per share upon warrant conversion
Rs. 20/-
Total funds raised from warrant conversion
Rs. 50,625,000.00/-
Total number of equity shares allotted to non-promoters
12,00,000
Issue price per share to non-promoters
Rs. 57/-
Total funds raised from non-promoter allotment
Rs. 68,400,000/-
Pre-allotment paid-up equity capital
Rs. 238,950,000.00/-
Post-allotment paid-up equity capital
Rs. 27,27,00,000.00/-
Post-allotment number of equity shares
27,270,000
🏢 How This Affects the Company
This fundraise through preferential allotment will enhance the company's financial resources for its operations and future growth initiatives.
The company's paid-up equity capital has increased. Post-allotment, paid-up capital is Rs. 27,27,00,000.00.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this allotment.
👤
Who Is Affected
Existing shareholders will experience dilution of their equity stake due to the issuance of new shares.
🔍
Management Signal
Management is actively pursuing capital raising through preferential issues to fund company operations and growth.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Subsequent quarterly results to show impact of new capital.
Monitoring of future fund-raising activities by the company.
Disclosure of utilization of funds raised from the preferential issues.
MEDIUM RISK
Dilution of existing shareholders' stake and differing issue prices raise concerns about valuation and fairness.
💡 Investor Takeaway
Novelix Pharmaceuticals raised a total of Rs. 13.59 Crore through preferential allotments, increasing paid-up capital to Rs. 27,27,00,000.00, comprising 27,270,000 shares.
⚖️ Strengths & Concerns
✅ Positives
- Raised Rs. 6.75 Crore via promoter warrant conversion at Rs. 20 per share, confirming promoter commitment.
- Successfully raised Rs. 6.84 Crore from non-promoter preferential issue at a higher price of Rs. 57 per share.
⚠️ Concerns
- Warrant conversion price of Rs. 20 per share is significantly lower than the Rs. 57 preferential issue price.
- Significant gap between face value (Rs. 10) and issue price (Rs. 20 and Rs. 57) indicates substantial premium components.
📅 Company Track Record
Previously, the company had announced preferential issues, including Rs. 1.73 Crore from promoter warrant conversion in March 2026 and Rs. 6.84 Crore via preferential issue in June 2026.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the total amount raised by Novelix Pharmaceuticals in this allotment?
Novelix Pharmaceuticals raised Rs. 50,625,000.00 from warrant conversion and Rs. 68,400,000/- from non-promoter allotment, totaling Rs. 119,025,000.00.
How many shares did Novelix Pharmaceuticals allot to promoters?
The company allotted 33,75,000 equity shares to promoters upon conversion of warrants at an issue price of Rs. 20/- each.
What is the issue price for the non-promoter preferential allotment?
Equity shares were allotted to non-promoters at an issue price of Rs. 57/- each, including a premium of Rs. 47/- per share.
How did the allotment affect Novelix Pharmaceuticals' paid-up capital?
The company's paid-up equity capital increased from Rs. 238,950,000.00 to Rs. 272,700,000.00 following the allotments.
Questions based on this BSE filing only. For information purposes.